Fusion Antibody Share News (FAB)
FAB Share
FAB Share
FAB Share
FAB Share
FAB
FAB Share
FAB Level 2
FAB Live
FAB Broker
FAB Directors
FAB Financial
FAB
FAB Short
FAB
Last checked at -
(Alliance News) - Fusion Antibodies PLC on Monday said that it has signed a commercial contract to develop an OptiPhage library for a non-human antibody species.
Read more(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:
Read more
(Sharecast News) - Fusion Antibodies announced the receipt of its first purchase order under a master services agreement on Tuesday, which it agreed with a prominent diagnostics company on 14 February.
Read more(Sharecast News) - Pre-clinical antibody specialist Fusion Antibodies announced a conditional fundraising of £1.38m before expenses on Wednesday, to help it target mo re industry conferences and customers and generate further supporting data.
Read moreFusion Antibodies PLC - Belfast-based contract researcher, which provides discovery, design and optimisation services for therapeutic antibodies to the healthcare market - Conditionally raises GBP1.4 million before expenses via placing of 34.4 million shares at 4 pence each. The issue price represents a discount of 5.9% to Fusion's closing mid-market share price on Tuesday. Further, it intends to issue 1.5 million new shares to certain directors in lieu of or in satisfaction of salary and fees due to them and which shall be issued immediately following publication of its announcement. Also intends to grant a total of up to 3.8 million new share options to staff and senior management.
Read more(Alliance News) - Fusion Antibodies PLC on Tuesday said it has won a follow-on project under a collaborative research and development agreement with an unnamed "US-based biotechnology company".
Read more(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.
Read more(Sharecast News) - Preclinical antibody discovery specialist Fusion Antibodies announced the successful receipt of a research and development tax credit from HMRC on Thursday.
Read more(Alliance News) - Fusion Antibodies PLC on Thursday announced the receipt of a research & development tax credit from UK HM Revenue & Customs for work performed on the development of its OptiMAL platform and other projects in bioinformatics.
Read more(Alliance News) - Stock prices in London closed lower on Monday, with miners and oil firms holding down the FTSE 100 index.
Read more(Sharecast News) - Contract research organisation Fusion Antibodies reported first-half revenue of £0.54m on Monday, down from £1.9m a year earlier.
Read more(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.
Read more(Alliance News) - Fusion Antibodies PLC on Monday reported a widened loss and reduced revenue for its latest half year, but said its growth prospects are "increasingly positive".
Read more(Alliance News) - Fusion Antibodies PLC on Tuesday said it has signed a collaboration agreement with the US National Cancer Institute to use its OptiMAL product to discover novel antibodies to treat certain targets.
Read more(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.
Read more
Last checked at